Merck's WELIREG Launch Marks a Milestone in PCPG Treatment Advancements Merck introduces WELIREG, the first oral therapy for pheochromocytoma and paraganglioma, reshaping advanced neuroendocrine tumor treatment.

Merck's WELIREG Launch Marks a Milestone in PCPG Treatment Advancements #USA #Las_Vegas #Merck #WELIREG #PCPG

FDA Approves Belzutifan (Welireg) for Advanced Pheochromocytoma and Paraganglioma: Results of LITESPARK-015 Trial - OncoDaily FDA approves belzutifan (Welireg) as first oral therapy for advanced pheochromocytoma and paraganglioma, based on LITESPARK-015 trial results.

FDA Approves Belzutifan (Welireg) for Advanced Pheochromocytoma and Paraganglioma: Results of LITESPARK-015 Trial
@fda.gov

oncodaily.com/oncolibrary/...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Belzutifan #Welireg #Pheochromocytoma #Paraganglioma #LITESPARK-015